We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $931M
1-Year Est. Return 41.63%
This Fund
S&P 500
This Quarter Est. Return
-25.4%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$2.39B
AUM Growth
-$1.3B
Cap. Flow
-$39.5M
Cap. Flow %
-1.65%
Top 10 Hldgs %
47.64%
Holding
157
New
7
Increased
9
Reduced
11
Closed
20

Top Buys

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$25.4M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$20.3M
3
VIGL
Vigil Neuroscience
VIGL
+$14.8M
4
IGMS
IGM Biosciences
IGMS
+$9.31M
5
APLS
Apellis Pharmaceuticals
APLS
+$8.83M

Top Sells

Rank Stock Value
1
FOLD
Amicus Therapeutics
FOLD
+$18.8M
2
NG icon
NovaGold Resources
NG
+$17.8M
3
ALBO
Albireo Pharma Inc
ALBO
+$14M
4
PTGX icon
Protagonist Therapeutics
PTGX
+$12.7M
5
KRYS icon
Krystal Biotech
KRYS
+$12.5M

Sector Composition

Rank Sector Weight
1 Healthcare 91.06%
2 Consumer Discretionary 6.64%
3 Miscellaneous 0.97%
4 Financials 0.85%
5 Consumer Staples 0.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DYN icon
76
Dyne Therapeutics
DYN
$3.34B
$5.06M 0.21%
525,000
– –
NEXI
77
DELISTED
NexImmune, Inc. Common Stock
NEXI
$5.05M 0.21%
48,000
– –
HARP
78
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$4.97M 0.21%
100,000
– –
SNTI icon
79
Senti Biosciences Holdings
SNTI
$9.34M
$4.93M 0.21%
50,000
– –
RNAC icon
80
Cartesian Therapeutics
RNAC
$239M
$4.92M 0.21%
133,333
– –
TIL icon
81
Instil Bio
TIL
$48.9M
$4.84M 0.2%
22,500
– –
YMAB
82
DELISTED
Y-mAbs Therapeutics
YMAB
$4.75M 0.2%
400,000
– –
RNAM
83
DELISTED
Avidity Biosciences
RNAM
$4.62M 0.19%
250,000
– –
BDTX icon
84
Black Diamond Therapeutics
BDTX
$113M
$4.56M 0.19%
1,646,517
– –
IVVD icon
85
Invivyd
IVVD
$245M
$4.56M 0.19%
+1,000,000
New +$6.12M
SPRO icon
86
Spero Therapeutics
SPRO
$65.8M
$4.35M 0.18%
500,000
– –
HOOK
87
DELISTED
HOOKIPA Pharma
HOOK
$4.22M 0.18%
184,962
+125,000
+208% +$2.24M
SYRS
88
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$4.17M 0.17%
350,000
+50,000
+17% +$894K
MIR icon
89
Mirion Technologies
MIR
$3.81B
$4.04M 0.17%
500,000
– –
ACIU icon
90
AC Immune
ACIU
$266M
$4M 0.17%
1,000,000
– –
ADVM
91
DELISTED
Adverum Biotechnologies
ADVM
$3.93M 0.16%
300,000
– –
PFTA
92
DELISTED
Perception Capital Corp. III Class A Ordinary Share
PFTA
$3.77M 0.16%
380,000
– –
SLDB icon
93
Solid Biosciences
SLDB
$897M
$3.6M 0.15%
200,000
– –
LENZ
94
LENZ Therapeutics
LENZ
$133M
$3.57M 0.15%
100,000
– –
LYEL icon
95
Lyell Immunopharma
LYEL
$267M
$3.54M 0.15%
35,000
– –
ADAG
96
Adagene
ADAG
$199M
$3.5M 0.15%
1,000,000
– –
VOR icon
97
Vor Biopharma
VOR
$1.32B
$3.32M 0.14%
27,500
– –
SANA icon
98
Sana Biotechnology
SANA
$946M
$3.3M 0.14%
400,000
– –
RXRX icon
99
Recursion Pharmaceuticals
RXRX
$1.74B
$3.22M 0.13%
450,000
+250,000
+125% +$2.66M
XLO icon
100
Xilio Therapeutics
XLO
$59.4M
$3.18M 0.13%
32,143
– –
2 3
4
5 6

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $931M AUM 47.97% 1-Year Est. Return
ACM
Ashe Capital Management Englewood Cliffs, New Jersey $931M AUM 4.95% 1-Year Est. Return
SAM
Sycomore Asset Management Paris, France $932M AUM 51.25% 1-Year Est. Return
NS
Night Squared New York $930M AUM 56.46% 1-Year Est. Return
PA
Planning Alternatives Birmingham, Michigan $933M AUM 28.32% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $933M AUM 56.2% 1-Year Est. Return
CICI
Capital Investment Counsel Inc Raleigh, North Carolina $929M AUM 53.07% 1-Year Est. Return
CAM
Claret Asset Management Montreal, Quebec, Canada $928M AUM 25.4% 1-Year Est. Return

Artal Group's Q1 2022 Portfolio in Review

As of Q1 2022, Artal Group held 157 positions worth $2.39B, down 35% from $3.69B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Artal Group's Q1 2022 filing shows 7 new, 9 increased, 11 reduced and 20 closed positions. Its largest new stake was Vigil Neuroscience: 1,121,191 shares worth $7.88M. The largest sale was Amicus Therapeutics, an estimated $18.8M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 84% a quarter earlier, followed by Consumer Discretionary and Miscellaneous.

  • Artal Group's largest Q1 2022 buy was Vigil Neuroscience: 1,121,191 shares worth $7.88M.
  • Artal Group added most to argenx in Q1 2022, an estimated $25.4M increase.
  • Artal Group's biggest Q1 2022 reduction was Amicus Therapeutics, cutting an estimated $18.8M.
  • Artal Group fully exited NovaGold Resources in Q1 2022, selling an estimated $17.8M.
  • Artal Group's ten largest holdings make up 48% of its $2.39B portfolio in Q1 2022.
  • Artal Group opened 7 new positions and closed 20 in Q1 2022.
  • Artal Group's portfolio value fell 35% quarter-over-quarter to $2.39B.

Based on Artal Group's 13F filing for Q1 2022, filed 12 May 2022.